DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.
Limitation of Use: DESCOVY FOR PrEP™ is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.
HIV risk persists for many people1
An estimated 40,000 new infections will be diagnosed this year in the United States (US)2
Approximately 1.1 million individuals are at risk of sexually acquired HIV. Risk affects people of all ethnicities, ages, and sexual orientations.2,3
- Black and Hispanic individuals have the highest lifetime risk among MSM4
- 17% of those diagnosed with HIV in 2016 were ≥50 years of age5
Despite these figures, less than 25% of the people at risk for HIV currently use PrEP as a prevention strategy2
The US government estimates that 250,000 total HIV infections could be averted within 10 years with widespread prevention efforts and has launched an initiative to expand PrEP awareness in appropriate patients.2
Help impact the HIV epidemic in your community by speaking to appropriate patients about HIV risk and DESCOVY FOR PrEP™.
MSM=men who have sex with men.